Cat. No.
MABL-3927
Application
antagonist, WB, Block, ELISA, FC, IF
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
Matuzumab
From
Recombinant Antibody
Specificity
This antibody binds the extracellular domain III of the human EGFR and does not cross react with murine EGFR. It was also reported that residues S460/G461 in EGFR domain III are essential components of the epitope. This antibody binds at a site distinct from the EGF binding site, preventing conformational re-arrangement required for dimerization, a process essential for high-affinitiy ligand binding (Schmiedel, 2008). This antibody can only recognize the active form of EGFR. The antibody binds to both glyco- and aglyco receptor forms. EGFR is a transmembrane mitogenic glycoprotein with a cytoplasmically facing tyrosine kinase site which is activated by binding of the epidermal growth factor in the external domain. It also binds transforming growth factor alpha (TGFa). EGFR a member of the epidermal growth factor family and is closely related to receptor tyrosine kinases. This receptor tyrosine kinase binds ligands of the EGF family and activates signallying cascades to convert extracellular cues into appropriate cellular responses. Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforme as well as inflammatory diseases.
Alternative Names
ErbB-1; ERBB1; HER1; EGF; Epidermal growth factor receptor; Proto- oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EMD72000; mAb425; 425; mAb 425
UniProt
P00533
Immunogen
Human EGFR.
Application Notes
The antibody binds specifically to EGFR, a cell-surface receptor which is part of the ErbB family of receptors. The EGFR is a receptor tyrosine kinase, which, upon activation by its ligands, such as epidermal growth factor and transforming growth factor alpha, triggers signal transduction pathways that increase cell migration, adhesion and proliferation. Mutations that lead to the overexpression of EGFR are associated with the development of cancer. The S3 12D antibody is prepared from isolation of phage antibodies of the spleen library.
Antibody First Published
Kettleborough et al. Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments. Eur. J. Immunol. 24 (4), 952-958 (1994) PMID:8149964
Note on publication
Describes the phage-antibody technology, which is used to produce three phage- antibody libraries from which mouse anti-EGFR scFv antibodies are generated. The libraries are prepared from the spleen, lymph node and in vitro cells of an immunized mouse. The antibodies produced are compared with a mouse mAb, 425, isolated by standard hybridoma technology.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
